Motsamai OI. Isoniazid preventive therapy (IPT): Botswana experience. Stop TB Symposium, Cape Town, 2007.
International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bulletin of the World Health Organization. 60: (4) 555-564, 1982.
Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. (1): CD000171, 2004.
Churchyard GJ et al. Efficacy of secondary isoniazid preventive therapy (IPT) among HIV-infected Southern Africans: time to change policy? AIDS 17: 2063-2070, 2003.
Golub JE et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 21: 1441–1448, 2007.
Cobelens FG et al. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clinical Infectious Diseases. 43: 634-639, 2006.
Quigley MA et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults.AIDS 15(2): 215-222, 2001.
Johnson JL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 15: 2137-2147, 2001.
Riska N. Hepatitis cases in Isoniazid treated groups and in a control group. Bulletin of the International Union Against Tuberculosis, 51:203-207, 1976.
American Thoracic Society and Centers for Disease Control and Prevention.Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161 :S221–S247, 2000.
Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a seven year survey from a public health clinic. JAMA 281: 1014–1018, 1999.
Eldred L et al. Lack of hepatotoxicity in patients on isoniazid preventive therapy (IPT) and antiretroviral therapy (ART). 38th World Lung Health Conference, Cape Town, abstract TS-71788-10, 2007.
Mngadi K et al. Adverse event experience in workplace settings with widespread isoniazid preventative therapy. 38th World Lung Health Conference, Cape Town, abstract PS-71835-10, 2007.
Nyirenda S et al. Isoniazid-associated hepatitis in people living with HIV (PLWH) during TB prophylactic therapy (IPT) – Botswana. 38th World Lung Health Conference, Cape Town, abstract PS-72134-11, 2007.
Popane F et al. Reasons for ineligibility for a community-wide isoniazid preventative therapy study. 38th World Lung Health Conference, Cape Town, abstract PS-72071-11, 2007.
Grant AD et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 293: 2719-2725, 2005.
Coetzee L et al. Interpreting good clinical practice for a community study. 38th World Lung Health Conference, Cape Town, abstract PS-71930-11, 2007.
Durovni B. Implementing isoniazid preventive therapy for people living with HIV: overcoming the barriers — perspective of the HIV programme. Stop TB Symposium, Cape Town, 2007.
Sutton BS et al. Cost-effectiveness of treatment for isoniazid preventive therapy among HIV-infected patients in Battambang, Cambodia. 38th World Lung Health Conference, Cape Town, abstract PS-71480-10, 2007.
Tamhane A et al. Inter-reader agreement for chest X-ray readings in HIV-infected pulmonary tuberculosis suspects, Battambang, Cambodia. 38th World Lung Health Conference, Cape Town, abstract PS-71464-11, 2007.
Mosimaneotsile B et al. Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana. Lancet 362: 1551-1552, 2003.
Mtei L et al. High rates of clinical and subclinical tuberculosis among HIV-infected am-bulatory subjects in Tanzania. Clinical Infectious Diseases 40(10): 1500-1507, 2005.
Chengeta B et al. Adherence to isoniazid TB preventive therapy (IPT) among people living with HIV (PLWH), Botswana, 2004-2006. 38th World Lung Health Conference, Cape Town abstract PS-72129-11, 2007.
WHO global tuberculosis programme/UNAIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV. Report of a meeting held in Geneva, 18-20 February 1998. Weekly Epidemiological Record, 74(46): 385-400, 1999.
Getahun H, Van Gorkom J, Harries A, Harrington M, Nunn P, Perriens J, et al. Interim policy on collaborative TB/HIV activities. Geneva, Switzerland. Stop TB Department and Department of HIV/AIDS. World Health Organization 2004.
*The Global TB/HIV Working Group is one of the seven Working Groups of the Stop TB Partnership established in 2001 to coordinate the global response to the dual TB and HIV epidemic. The Core Group is the decision making body which sets the strategic directions of the Working Group and makes recommendations on the global response to the TB and HIV co-infection epidemic.